GZBL(SZ:002424) Xin Lang Cai Jing·2025-11-12 02:58Core Points - Guizhou BaiLing's stock price increased by 2.16% on November 12, reaching 6.14 CNY per share, with a total market capitalization of 8.581 billion CNY [1] - The company has seen a year-to-date stock price increase of 59.48%, with a 3.72% rise in the last five trading days and a 13.49% rise over the last 20 days [1] - For the period from January to September 2025, Guizhou BaiLing reported a revenue of 2.102 billion CNY, a year-on-year decrease of 24.28%, and a net profit of 56.8144 million CNY, down 35.60% year-on-year [2] Company Overview - Guizhou BaiLing Pharmaceutical Group Co., Ltd. was established on March 25, 1999, and went public on June 3, 2010, primarily engaged in the production and sales of traditional Chinese medicine, particularly苗药 [1] - The company's revenue composition includes 86.97% from traditional Chinese medicine, 8.44% from Western medicine, 2.27% from medical services, 1.91% from other sources, and 0.42% from Chinese medicinal materials [1] Shareholder Information - As of October 20, 2025, Guizhou BaiLing had 96,300 shareholders, an increase of 15.19% from the previous period, with an average of 12,597 circulating shares per shareholder, a decrease of 13.19% [2] - The company has distributed a total of 1.447 billion CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 14.0733 million shares as a new shareholder [3]